Bridel et al. [78] showed that NF-L is associated with progression in Natalizumab-treated patients with RR-MS, whereas Kuhle et al. [79] showed a reduction in sNF-L following early alemtuzumab treatment in RR-MS patients. Here, NEFL is linked to myeloid sarcoma.